Synvista Therapeutics Announces Initiation Of Phase 2 Study With Alagebrium For Chronic Heart Failure
Nov 18th 2007Drug InformationCardiovascular
Synvista Therapeutics, Inc. (AMEX: SYI) announced , dosing of the first patient in BENEFICIAL, a 100-patient Phase 2 clinical trial of alagebrium (ALT-711), a novel compound designed to act as an Advanced Glycation End-product (AGE)-cross-link breaker, in patients with chronic heart failure (CHF). [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
